Financial Health Assessment: FAULKNER HOLDINGS LIMITED

1. Financial Health Score: D+

Explanation: The patient is alive but suffering from a chronic, progressive condition. While the company remains technically solvent with positive net assets and adequate short-term liquidity, it has experienced relentless deterioration in financial health over nearly a decade. Total assets have declined by approximately 85% since 2016, and equity has been steadily eroded through accumulated losses. This is a business in secular decline – not facing an acute crisis, but on a concerning trajectory.

2. Key Vital Signs

Interpretation of Vital Signs

Blood Pressure (Cash Position): The most alarming symptom. Cash has plummeted from £99,121 in 2023 to £22,664 in 2025 – a 77% decline over two years. This represents a significant hemorrhage of the company's most liquid asset. The "healthy cash flow" this business once enjoyed has become dangerously thin.

Heart Rate (Asset Base): Total assets have been in consistent, unbroken decline for nine consecutive years, falling from £850,861 in 2016 to £123,179 in 2025. This is the financial equivalent of chronic weight loss – the business is steadily consuming itself.

Cholesterol (Liabilities vs Assets): The current ratio of 2.27:1 appears healthy on the surface, but this is somewhat deceptive. The improvement from 1.87:1 is primarily due to the significant reduction in amounts owed to group undertakings (from £41,754 to £3,000), rather than genuine operational improvement.

Body Temperature (Profitability): The P&L reserve has declined from £74,369 to £40,465 over the latest 15-month period, representing a loss of approximately £33,904. The company is running a persistent fever of losses.

3. Diagnosis

What the Financial Data Reveals About Business Health

Primary Condition: Chronic Atrophic Decline

This company presents a textbook case of gradual business atrophy. As a holding company (SIC 70100 - Activities of head offices) with zero employees, it appears to be slowly liquidating its asset base rather than actively trading or growing.

Key Pathological Findings:

1. Asset Erosion: The near-total depreciation of tangible assets (£3,677 net book value from an original cost of £186,542) indicates the company has not reinvested in its asset base. The plant and machinery are effectively at end-of-life.

2. Investment Write-down: Investments dropped from £10,266 to £nil, suggesting either disposal or impairment – potentially a subsidiary or associate has been sold or written off.

3. Intercompany Deleveraging: The dramatic reduction in amounts owed to group undertakings (from £41,754 to £3,000) suggests the company has settled or restructured obligations within its group, which may indicate broader group restructuring.

4. Receivables Dependency: Trade debtors of £76,038 represent 62% of total assets and 333% of cash. The business is heavily dependent on collecting what it is owed. A significant bad debt could be terminal.

5. Nine-Year Decline Trajectory: The unbroken decline in net assets from £370,568 (2016) to £70,567 (2025) represents an 81% erosion of shareholder value. This is not a temporary illness but a progressive condition.

Differential Diagnosis: - The company may be in managed wind-down mode, deliberately running off obligations - It may be a dormant or near-dormant entity within a group structure - The change in accounting period (from March year-end to June year-end) may signal restructuring activity

4. Recommendations

Immediate Actions (Emergency Treatment)

1. Cash Preservation: With only £22,664 in cash and no visible revenue generation mechanism, the company must urgently address its cash burn rate. Review all outflows and eliminate non-essential expenditure.

2. Debtor Collection: Trade debtors of £76,038 are the largest asset. Implement aggressive but professional collection procedures. Every pound collected directly strengthens the cash position.

3. Strategic Clarity: Directors should formally document the company's strategic purpose. Is this entity meant to continue trading, or is it in managed wind-down? Stakeholders deserve transparency.

Medium-Term Actions (Rehabilitation Programme)

4. Asset Realisation Review: Evaluate whether remaining tangible assets (£3,677 net book value) and stock (£2,065) can be monetised more effectively.

5. Group Structure Assessment: Given the intercompany balances and holding company status, review whether this entity serves a necessary function within the broader group, or whether consolidation or voluntary dissolution would be more efficient.

6. Governance Review: With six officers (including dual roles for Honora Balcomb as both director and secretary) and zero employees, ensure the governance structure remains appropriate and that directors are fulfilling their statutory duties regarding the consistent decline in shareholder value.

Long-Term Actions (Preventative Care)

7. Viability Statement: The directors should prepare a formal assessment of whether the company can continue as a going concern. With equity declining by approximately £30,000-£40,000 annually, the company could reach negative net assets within 2-3 years if trends continue.

8. Consider Voluntary Strike-Off: If the company no longer serves a commercial purpose, directors should consider whether dissolution would be more appropriate than continued operation with eroding value.

Prognosis

Guarded to Poor

Without significant intervention or a change in strategic direction, this company faces continued decline. At the current rate of equity erosion (averaging approximately £33,000 per year over the past three years), net assets could be exhausted within 2-3 years. The "immune system" (cash reserves) has been severely depleted, leaving the business vulnerable to any unexpected shock.

However, the adequate current ratio and positive net assets suggest there is still time for recovery or managed wind-down – the patient is not yet in terminal condition, but urgent lifestyle changes are required.